Biotech | May 02, 2022
Xcardia announces first-in-human use of its new Xtractor device
The announcement follows FDA 510(k) clearance of device
The announcement follows FDA 510(k) clearance of device
Three RFPs now open for qualified researchers through NORD's Jayne Holtzer rare disease research grants program
CIVCO RT will also display its recent innovations focusing on improving patient comfort and outcomes
Avacc 3 has significant advantages over existing whooping cough vaccines
Blood test for early detection of Alzheimer's Disease (AD) risk will lead to better patient care, physicians say; US. adults call for earlier evaluation and more education
ABDM is a critical integration that leverages an open, interoperable, standards-based digital system that is secure, and maintains confidentiality and privacy of health-related personal information
The companies expect to complete the submission of the NDA for treatment of MDD in the second half of 2022; associated filing for postpartum depression is anticipated in the first half of 2023
Onshore manufacturing facility is expected to be based in Quebec and produce up to 100 million mRNA respiratory vaccine doses annually
CLNK is a biotechnology research and development company that utilizes umbilical cord blood as the raw material to develop innovative, allogeneic, off-the-shelf, cell based therapeutic products
The planned Phase 1 study is a double-blind, randomized, placebo-controlled dose-escalation study in healthy adult subjects and AD patients
Subscribe To Our Newsletter & Stay Updated
